These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20887595)

  • 1. Lower circulating levels of dehydroepiandrosterone, independent of insulin resistance, is an important determinant of severity of non-alcoholic steatohepatitis in Japanese patients.
    Sumida Y; Yonei Y; Kanemasa K; Hara T; Inada Y; Sakai K; Imai S; Hibino S; Yamaguchi K; Mitsuyoshi H; Yasui K; Minami M; Itoh Y; Naito Y; Yoshikawa T; Okanoue T
    Hepatol Res; 2010 Sep; 40(9):901-10. PubMed ID: 20887595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease.
    Charlton M; Angulo P; Chalasani N; Merriman R; Viker K; Charatcharoenwitthaya P; Sanderson S; Gawrieh S; Krishnan A; Lindor K
    Hepatology; 2008 Feb; 47(2):484-92. PubMed ID: 18220286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients.
    Koehler E; Swain J; Sanderson S; Krishnan A; Watt K; Charlton M
    Liver Int; 2012 Feb; 32(2):279-86. PubMed ID: 22098614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower levels of insulin-like growth factor-1 standard deviation score are associated with histological severity of non-alcoholic fatty liver disease.
    Sumida Y; Yonei Y; Tanaka S; Mori K; Kanemasa K; Imai S; Taketani H; Hara T; Seko Y; Ishiba H; Okajima A; Yamaguchi K; Moriguchi M; Mitsuyoshi H; Yasui K; Minami M; Itoh Y
    Hepatol Res; 2015 Jul; 45(7):771-81. PubMed ID: 25163357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
    Ozturk O; Colak Y; Senates E; Yilmaz Y; Ulasoglu C; Doganay L; Ozkanli S; Oltulu YM; Coskunpinar E; Tuncer I
    World J Gastroenterol; 2015 Jul; 21(26):8096-102. PubMed ID: 26185381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower levels of dehydroepiandrosterone sulfate are associated with more advanced liver fibrosis in chronic hepatitis C.
    de Araujo Neto JM; Coelho HSM; Chindamo MC; Rezende GFM; Nunes Pannain VL; Bottino AMCF; Bruzzi Porto LF; Luiz RR; Villela-Nogueira CA; Perez RM
    J Viral Hepat; 2018 Mar; 25(3):254-261. PubMed ID: 29091323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease.
    Tokushige K; Hashimoto E; Kodama K; Tobari M; Matsushita N; Kogiso T; Taniai M; Torii N; Shiratori K; Nishizaki Y; Ohga T; Ohashi Y; Sato T
    J Gastroenterol; 2013 Dec; 48(12):1392-400. PubMed ID: 23478936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
    Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
    Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
    Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
    J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
    J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment.
    Ballestri S; Nascimbeni F; Romagnoli D; Lonardo A
    Hepatol Res; 2016 Oct; 46(11):1074-1087. PubMed ID: 26785389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum adiponectin levels in different types of non alcoholic liver disease. Correlation with steatosis, necroinflammation and fibrosis.
    Arvaniti VA; Thomopoulos KC; Tsamandas A; Makri M; Psyrogiannis A; Vafiadis G; Assimakopoulos SF; Labropoulou-Karatza C
    Acta Gastroenterol Belg; 2008; 71(4):355-60. PubMed ID: 19317274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FICK-3 Score Combining Fibrosis-4, Insulin Resistance and Cytokeratin-18 in Predicting Non-alcoholic Steatohepatitis in NAFLD Egyptian Patients.
    Mohammed MA; Omar NM; Mohammed SA; Amin AM; Gad DF
    Pak J Biol Sci; 2019 Jan; 22(10):457-466. PubMed ID: 31930835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
    Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive estimation of disease activity and liver fibrosis in nonalcoholic fatty liver disease using anthropometric and biochemical characteristics, including insulin, insulin resistance, and 13C-methionine breath test.
    Korkmaz H; Unler GK; Gokturk HS; Schmidt WE; Kebapcilar L
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1137-43. PubMed ID: 26049707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: a study in Brazilian patients.
    Domenici FA; Brochado MJ; Martinelli Ade L; Zucoloto S; da Cunha SF; Vannucchi H
    Gene; 2013 Oct; 529(2):326-31. PubMed ID: 23891824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum biomarkers in type 2 diabetic patients with non-alcoholic steatohepatitis and advanced fibrosis.
    Leite NC; Salles GF; Cardoso CR; Villela-Nogueira CA
    Hepatol Res; 2013 May; 43(5):508-15. PubMed ID: 23067270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of spleen volume is useful for distinguishing between simple steatosis and early-stage non-alcoholic steatohepatitis.
    Suzuki K; Kirikoshi H; Yoneda M; Mawatari H; Fujita K; Nozaki Y; Takahashi H; Abe Y; Inamori M; Shimamura T; Kobayashi N; Kubota K; Saito S; Nakajima A
    Hepatol Res; 2010 Jul; 40(7):693-700. PubMed ID: 20412325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.